NasdaqGS:EXELBiotechs
Is Exelixis (EXEL) Using Zanzalintinib To Quietly Redefine Its Post-Cabometyx Strategy?
Exelixis recently submitted a US FDA application for its next-generation cancer drug zanzalintinib, seeking approval in combination with Roche’s Tecentriq for previously treated metastatic colorectal cancer.
This filing highlights how Exelixis is leaning on its emerging pipeline to address future generic pressure on flagship therapy Cabometyx.
Next, we’ll examine how advancing zanzalintinib toward potential approval could influence Exelixis’ investment narrative and long-term oncology...